Scholarlink

Background <p>Smoking is the leading preventable risk factor for lung cancer and continues to affect prognosis, treatment tolerance and comorbidity after cancer diagnosis. Nevertheless, structured smoking cessation support remains insufficiently implemented in oncology care.</p> Objectives <p>This narrative review summarizes current evidence on the effectiveness of smoking cessation in patients with cancer, with a&#xa0;focus on lung cancer, and analyzes biological, clinical and health economic arguments supporting its implementation as standard therapy.</p> Materials and methods <p>A&#xa0;narrative review based on PubMed-listed original literature from 2010 to 2026 was performed. Particular emphasis was placed on systematic reviews, meta-analyses, guidelines and selected recent original studies addressing survival, recurrence, second primary malignancies, treatment interactions, intervention efficacy and health economic outcomes.</p> Results <p>Smoking cessation at diagnosis or shortly thereafter is associated with improved overall survival in lung cancer. In patients with cancer, combined behavioural and pharmacological cessation interventions show the most consistent benefit for abstinence. Additional evidence indicates reduced risk of second primary lung cancer and favourable economic effects of integrated cessation programs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aktuelle Evidenz zur Wirksamkeit der Tabakentwöhnung bei Tumorpatienten mit Fokus Lungenkarzinom: biologische, klinische und gesundheitsökonomische Aspekte zur Etablierung als Standardtherapie inkl. praktischer Umsetzung

  • 期刊论文

  • 发表日期：

    2026年6月16日

查看全文
  • Matthias Urlbauer,
  • Matthias Raspe,
  • Karin Vitzthum,
  • Joachim Ficker

摘要

Background

Smoking is the leading preventable risk factor for lung cancer and continues to affect prognosis, treatment tolerance and comorbidity after cancer diagnosis. Nevertheless, structured smoking cessation support remains insufficiently implemented in oncology care.

Objectives

This narrative review summarizes current evidence on the effectiveness of smoking cessation in patients with cancer, with a focus on lung cancer, and analyzes biological, clinical and health economic arguments supporting its implementation as standard therapy.

Materials and methods

A narrative review based on PubMed-listed original literature from 2010 to 2026 was performed. Particular emphasis was placed on systematic reviews, meta-analyses, guidelines and selected recent original studies addressing survival, recurrence, second primary malignancies, treatment interactions, intervention efficacy and health economic outcomes.

Results

Smoking cessation at diagnosis or shortly thereafter is associated with improved overall survival in lung cancer. In patients with cancer, combined behavioural and pharmacological cessation interventions show the most consistent benefit for abstinence. Additional evidence indicates reduced risk of second primary lung cancer and favourable economic effects of integrated cessation programs.